Vascular neurological complications in patients with COVID-19

April 19, 2021
934
Resume

The article considers modern views on the development and course of coronavirus infection COVID-19. Particular attention is paid to vascular neurological complications. Edaravon and citicoline with electrolytes were used to optimize the treatment of cerebrovascular complications in patients with concomitant COVID-19. Clinical and paraclinical data of 34 patients were analyzed. As a result, it is proved that this combination of drugs significantly increases the therapeutic efficacy of the basic treatment regimens of this group of patients and can be recommended for widespread use in medical practice.

References:

  • 1. Chu H., Chan J.F., Yuen T.T. et al. (2020) Comparative tropism, replication kinetics, and cell damage profiling of SARSCoV-2 and SARS-CoV with implications for clinical manifestations, transmissibility, and laboratory studies of COVID-19: an observational study. Lancet Microbe, 1(1): 14–23.
  • 2. Huang C., Wang Y., Li X. et al. (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 395 (10223): 497–506.
  • 3. Wang D.,Hu B., Hu C. et al. (2020) Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus‐infected pneumonia in Wuhan, China. JAMA, 323(11): 1061–1069.
  • 4. Chen N., Zhou M., Dong X. et al. (2020) Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet, 395(10223): 507–513.
  • 5. Spinato G., Fabbris C., Polesel J. et al. (2020) Alterations in Smell or Taste in Mildly Symptomatic Outpatients with SARS-CoV-2 Infection. JAMA, 323(20): 2089–2090.
  • 6. Mao L., Wang M., Chen Sh., He Q. (2020) Neurological Manifestations of Hospitalized Patients with COVID-19 in Wuhan, China: a retrospective case seriesstudy. JAMA Neurol., 77(6): 683–690.
  • 7. Yee K.M. (2020) Researchers outline neurological signs of COVID-19. Aunt. Minnie, Jul. 8.
  • 8. Chatterjee P., Nagi N., Agarwal A. et al. (2020) The 2019 novel coronavirus disease (COVID-19) pandemic: A review of the current evidence. Indian J. Med. Res., 151(2 & 3): 147–159. doi: 10.4103/ijmr.IJMR_519_20.
  • 9. Spyropoulos A.C., Levy J.H., Ageno W. et al. (2020) Scientific and Standardization Committee communication: Clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID‐19 (https://onlinelibrary.wiley.com/doi/full/10.1111/jth.14929).
  • 10. Zhang Zh.-W., Xu X.-Ch., Liu T., Yuan Sh. (2015) Mitochondrion-Permeable Antioxidants to Treat ROS-Burst-Mediated Acute Diseases. Oxid Med. Cell Longev., 2016: 6859523. doi: 10.1155/2016/6859523.
  • 11. Ikeda S., Harada K., Ohwatashi A. et al. (2013) Effects of edaravone, a free radical scavenger, on photochemically induced cerebral infarction in a rat hemiplegic model. Sci. World J., Published online, Jun. 17.
  • 12. Hashimoto S., Sanui M., Egi M. et al. (2017) The clinical practice guideline for the management of ARDS in Japan. J. Intensive Care, 5: 50.
  • 13. Saito Y., Fujii Y., Yashiro M. et al. (2015) Inhibitory Effects of Edaravone, a Free Radical Scavenger, on Cytokineinduced Hyperpermeability of Human Pulmonary Microvascular Endothelial Cells: A Comparison with Dexamethasone and Nitric Oxide Synthase Inhibitor. Acta Med. Okayama, 69(5): 279–290.
  • 14. Ministry of Health of Ukraine (2020) Order of the Ministry of Health of Ukraine dated 17.09.2020 № 2116 «About modification of the protocol «Provision of medical care for the treatment of coronavirus disease (COVID-19)» (https://moz.gov.ua/article/ministry-mandates/nakaz-moz-ukraini-vid-17092020–2116pro-vnesennja-zmin-do-protokolu–nadannja-medichnoi-dopomogi-dlja-likuvannja–koronavirusnoi-hvorobi-covid-19) (In Ukr.).